Investor's Business Daily on MSN21m
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone
Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged.
Investor's Business Daily on MSN21m
Novocure Launches 49% After Pancreatic Cancer Treatment Succeeds
Novocure stock catapulted early Monday after the company's cancer-treating device succeeded in a study of patients with pancreatic cancer.
BioPharma Dive5h
Novocure device succeeds in pancreatic cancer study; FDA sets Cytokinetics decision date
Using tumor-treating fields alongside chemotherapy improved patient survival, Novocure said. Elsewhere, Cytokinetics got a ...
This Stock Just Dropped by 12% in 1 Day: Should You Buy the Dip?
The biotech industry can be volatile even for relatively large companies. Amgen ( AMGN 1.00%), one of the more prominent names in the game, just reminded us all of that fact. On Nov. 26, the company's ...
FiercePharma8h
Race is on for oral obesity drugs with multiple phase 3 trials vying for next-gen status in a $126B market
Unless you have been living under a rock, you’ll know that anti-obesity GLP-1 drugs are the next big thing in pharma, with ...